Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. by Carroccio, A. et al.
NON-CELIAC WHEAT SENSITIVITY DIAGNOSED BY DOUBLE-BLIND PLACEBO-CONTROLLED 
CHALLENGE: EXPLORING A NEW CLINICAL ENTITY 
 
Antonio Carroccio (1), Pasquale Mansueto (2), Giuseppe Iacono (3), Ada M Florena (4), Alberto D’Alcamo (2), 
Aurelio Seidita (2), Francesca Cavataio (3), Ignazio Brusca (5), Maurizio Soresi (2), Giuseppe Ambrosiano (2), 
Giuseppe Pirrone (2), Giovanni Battista Rini (2) 
 
1) Internal Medicine, Hospital of Sciacca, ASP Agrigento, Italy 
2) Internal Medicine, Policlinico University Hospital of Palermo, Italy 
3) Pediatric Gastroenterology, “Di Cristina” Hospital, Palermo, Italy 
4) Pathology, Policlinico University Hospital of Palermo, Italy 
5) Clinical Chemistry, Buccheri-La Ferla Hospital, Palermo, Italy 
 
ABSTRACT 
Background and Aims: Non-celiac wheat sensitivity (WS) is considered a new clinical entity. An increasing percentage 
of the general population avoids gluten ingestion. However, the real existence of this entity is debated and markers for 
this condition are lacking. We aimed to demonstrate the existence of WS and define its clinical, serologic and 
histological markers.  
Methods: We reviewed the clinical charts of all subjects who had been diagnosed with wheat sensitivity (WS) using a 
double-blind placebo-controlled challenge (DBPCC) from 2001-2010. One hundred CD patients served as controls. 
Results: Four hundred and seven patients with WS were included, as diagnosed by DBPCC. Two groups showing 
distinct clinical characteristics were identified: wheat sensitivity alone (Group 1) and wheat sensitivity associated with 
multiple food hypersensitivity (Group 2). Group 1 WS was characterized by clinical features very similar to those found 
in CD patients: all subjects showed the HLA DQ2 and/or DQ8 haplotypes, EmA assay in the culture medium of the 
intestinal biopsies was positive in 27% and duodenal lymphocytosis was seen in 94% of cases. Group 2 WS was 
characterized by a high frequency of IBS, the presence of HLA DQ2 or DQ8 haplotype in 50% of cases, a high 
frequency of positive serum anti-gliadin IgG (60%) and basophil in vitro activation with wheat antigen stimulation 
(80%), as well as eosinophil infiltration of the duodenal (47%) and colon (67%) mucosa. 
Conclusions: Our data confirm the existence of not-celiac WS as a distinct clinical condition. We also suggest the 
existence of two distinct populations of subjects with WS: one with characteristics more similar to CD and the other 
with characteristics pointing to food allergy. 
